ISRCTN49411996已完成4 期
VIVALDI: Valdoxan® improves depressive symptoms and normalises circadian rhythms - an observational prospective study
Servier Deutschland GmbH (Germany)0 个研究点目标入组 8,000 人开始时间: 2009年5月15日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 8,000
研究概览
简要总结
- 2012 results in https://www.ncbi.nlm.nih.gov/pubmed/22592503 (added 18/01/2019)
研究设计
- 研究类型
- Observational
入排标准
- 性别
- All
入选标准
- •1. Both males and females, adult patients (>=18 years)
- •2. Episodes of major depression
排除标准
- •Does not meet inclusion criteria
研究者
相似试验
已完成
4 期
VIVALDI Praxis: Valdoxan improves depressive symptoms and normalizes circadian rhythmsEpisodes of major depressionMental and Behavioural DisordersRecurrent depressive disorderISRCTN18801971Servier Deutschland GmbH (Germany)3,600
已完成
不适用
VIVID-ONValdoxan® improves vitality in depression with anhedoniaF32Depressive episodeDRKS00011602Servier Deutschland GmbH970
已完成
不适用
Valdoxan ImproVes depRession with anxiEty symptoms (VIVRE)Episodes of major depressionMental and Behavioural DisordersRecurrent depressive disorder, current episode severeISRCTN20363887Servier Deutschland GmbH (Germany)3,000
已完成
不适用
VITAL Germany (Valdoxan® Improves Treatment of depression and daytime Activity in real Life)Episodes of major depressionMental and Behavioural DisordersDepressive episodeISRCTN44890666Servier Deutschland GmbH (Germany)3,005
已完成
4 期
Safety and Efficacy of Vilazodone in Major Depressive DisorderMajor Depressive DisorderNCT01573598Forest Laboratories1,219